PerkinElmer PT receives Investment Bank Analyst Rating Update
By Investing.com Staff Today's most important analyst stock upgrades: Deutsche Bank upgraded Estee Lauder (NYSE:EL) from Hold to Buy with a price target of $266.00 on the...
By Sam Boughedda Cowen analysts upgraded shares of PerkinElmer (NYSE:PKI) to Outperform from Market Perform, cutting the price target to $164 from $192 in a note Tuesday. They said...
The S&P showed us how it’s done on Thursday by not only reaching a new intraday record (as the Dow did yesterday), but also finishing the session at a fresh closing...
PerkinElmer (NYSE:PKI), Inc. PKI reported second-quarter 2021 adjusted earnings per share (EPS) of $2.83, which beat the Zacks Consensus Estimate of $2.41 per share by 17.4%. The...
PerkinElmer (NYSE:PKI) shares soared 6.9% in the last trading session to close at $136.57. The move was backed by solid volume with far more shares changing hands than in a normal...
PerkinElmer, Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides products and services targeted towards the life sciences and applied markets. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. The Company provides early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market. It offers its products under various brand names, including AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BoBs, chemagic, Chitas, Datalytix, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROline, EUROPattern, FragilEase, Genoglyphix, GSP, and others.
|Average||160.71 (+16.54% Upside)|
|No. of Analysts||14|